City of Hope | Strategic Alliance Partners

Latest from City of Hope

Checkpoint and PARP Inhibition Remain the Focus of Ongoing Research in TNBC

March 10, 2021

The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

March 03, 2021

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.